Biodesix skyrockets 43%, expects FY revenue to beat guidance
Source: SeekingAlpha
2026-01-12 07:17:30 ET
More on Biodesix
- Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript
- Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates
- Seeking Alpha’s Quant Rating on Biodesix
- Historical earnings data for Biodesix
- Financial information for Biodesix
Read the full article on Seeking Alpha
For further details see:
Biodesix skyrockets 43%, expects FY revenue to beat guidance
Biodesix Inc.
NASDAQ: BDSX
BDSX Trading
1.26% G/L:
$19.28 Last:
37,157 Volume:
$19.30 Open:
BDSX Latest News
February 26, 2026 04:01:00 pm
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
BDSX Stock Data
$83,296,022
3,850,552
19.65%
10
N/A
Medical Diagnostics & Screening
Healthcare
US
Louisville
